[
  {
    "ts": null,
    "headline": "Revvity wins FDA clearance for ChLIA assay in free testosterone measurement",
    "summary": "The authorisation marks the first for a ChLIA in direct and quantitative free testosterone testing.",
    "url": "https://finnhub.io/api/news?id=3b9edfe5c7512b5d6888182d2d85485ad5ea131ec906b8e8a1a03012b185d262",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736527031,
      "headline": "Revvity wins FDA clearance for ChLIA assay in free testosterone measurement",
      "id": 132369388,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/23/2025/01/shutterstock_1923152264.jpg",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "The authorisation marks the first for a ChLIA in direct and quantitative free testosterone testing.",
      "url": "https://finnhub.io/api/news?id=3b9edfe5c7512b5d6888182d2d85485ad5ea131ec906b8e8a1a03012b185d262"
    }
  },
  {
    "ts": null,
    "headline": "Revvity Announces FDA Clearance for First Automated Free Testosterone Test",
    "summary": "WALTHAM, Mass., January 10, 2025--Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders.",
    "url": "https://finnhub.io/api/news?id=12383ce947b37ba523e3280d4f488cd42b9b1964ce3b7c4d3736919b73be5d3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736514000,
      "headline": "Revvity Announces FDA Clearance for First Automated Free Testosterone Test",
      "id": 132369389,
      "image": "https://media.zenfs.com/en/business-wire.com/3efc21190dcd78fb2e6f2f54177bb324",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., January 10, 2025--Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders.",
      "url": "https://finnhub.io/api/news?id=12383ce947b37ba523e3280d4f488cd42b9b1964ce3b7c4d3736919b73be5d3f"
    }
  }
]